Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > EU approves first I/O combination

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 16, 2024 6:36pm

146 Views

Post# 35830176

RE:RE:RE:RE:RE:EU approves first I/O combination

The essence of these developments is that the state of the immuno-oncology sector is dynamic and is positively moving forward, towards an increasing recognition of the benefit of selectively combining I/O agents such as immuno-modulators (i.e. pelareorep) + immune checkpoint inhibitors + chemotherapy (i.e nab-paciltaxel) in the effective treatment of multiple cancers. Furthermore pelareorep is also able to be combined with ADCs, CAR-T therapy and small molecules in an evolving and increasingly dynamic I/O treatment acquisition environment.

<< Previous

Bullboard Posts

Next >>

Enbridge finalizes acquisition of three growing gas utilities